Inhibitory Effects of a Novel μ-Opioid Receptor Nonpeptide Antagonist, UD-030, on Morphine-Induced Conditioned Place Preference
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24043351 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Soichiro Ide und 6 weiteren Autor:innen. Beteiligte Einrichtung: Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan. Hauptthemen laut MEDLINE: Narcotic Antagonists, Opioid-Related Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, UBE Corporation, JSPS.
Abstract (Originalsprache)
Although opioids are widely used to treat moderate to severe pain, opioid addiction and the opioid overdose epidemic are becoming more serious. Although opioid receptor antagonists/partial agonists, such as naltrexone and buprenorphine, have relatively low selectivity for the μ-opioid receptor (MOP), they have been used for the management of opioid use disorder. The utility of highly selective MOP antagonists remains to be evaluated. Here, we biologically and pharmacologically evaluated a novel nonpeptide ligand, UD-030, as a selective MOP antagonist. UD-030 had more than 100-fold higher binding affinity for the human MOP (Ki = 3.1 nM) than for δ-opioid, κ-opioid, and nociceptin receptors (Ki = 1800, 460, and 1800 nM, respectively) in competitive binding assays. The [35S]-GTPγS binding assay showed that UD-030 acts as a selective MOP full antagonist. The oral administration of UD-030 dose-dependently suppressed the acquisition and expression of morphine-induced conditioned place preference in C57BL/6J mice, and its effects were comparable to naltrexone. These results indicate the UD-030 may be a new candidate for the treatment of opioid use disorder, with characteristics that differ from traditional medications that are in clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
- UBE Corporation, Yamaguchi 755-8633, Japan.
- Sanwa Kagaku Kenkyusho Co., Ltd., Aichi 461-8631, Japan.
ORCID-Profile: Kazutaka Ikeda
Förderung
- Japan Society for the Promotion of Science
- UBE Corporation
- JSPS
Zitieren
APA
Ide, S., Iwase, N., Arai, K., Kojima, M., Ushiyama, S., Taniko, K., & Ikeda, K. (2023). Inhibitory Effects of a Novel μ-Opioid Receptor Nonpeptide Antagonist, UD-030, on Morphine-Induced Conditioned Place Preference. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043351
Vancouver
Ide S, Iwase N, Arai K, Kojima M, Ushiyama S, Taniko K, et al. Inhibitory Effects of a Novel μ-Opioid Receptor Nonpeptide Antagonist, UD-030, on Morphine-Induced Conditioned Place Preference. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043351
BibTeX
@article{Ide2023,
author = {Ide, Soichiro and Iwase, Noriaki and Arai, Kenichi and Kojima, Masahiro and Ushiyama, Shigeru and Taniko, Kaori and Ikeda, Kazutaka},
title = {Inhibitory Effects of a Novel μ-Opioid Receptor Nonpeptide Antagonist, UD-030, on Morphine-Induced Conditioned Place Preference},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24043351}
}
EUVIMED